[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645345":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":44,"responsibleParty":144,"collaborators":148,"id":152,"slug":153,"hasResults":154,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":154,"sex":160,"minAge":161,"maxAge":25,"enrollmentInfo":162,"targetDuration":25,"studyType":165,"phases":166,"briefSummary":168,"conditions":169,"keywords":171,"overallStatus":175,"whyStopped":25,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":185},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Low-risk group（Without del17p and\u002For TP53 mutation）","EXPERIMENTAL","12 cycles of zanubrutinib monotherapy induction → 12 cycles of zanubrutinib combined with sonrotoclax → discontinuation of study drugs followed by regular follow-up",[13],"Drug: 12 cycles of zanubrutinib followed by 12 cycles of zanubrutinib in combination with sonrotoclax",{"label":15,"type":10,"description":16,"interventionNames":17},"High-risk group(With del17p and\u002For TP53 mutation)","12 cycles of zanubrutinib followed by 12 cycles of zanubrutinib in combination with sonrotoclax, then zanubrutinib maintenance monotherapy until disease progression or intolerable toxicity occurs.",[13,18],"Drug: zanubrutinib maintenance until disease progression",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","12 cycles of zanubrutinib followed by 12 cycles of zanubrutinib in combination with sonrotoclax","12 cycles of zanubrutinib monotherapy induction → 12 cycles of zanubrutinib combined with sonrotoclax → discontinuation of study drugs followed by regular follow-up Zanubrutinib Dosage The total daily oral dose is 320 mg. The dosing schedule is 160 mg (2 × 80 mg capsules) twice daily, Sonrotoclax Dose Escalation Schedule\n\nCycle 13 Week 1 (C13W1):\n\nDays 1-3: 1 mg daily (1 × 1 mg tablet); Days 4-7: 2 mg daily (2 × 1 mg tablets)\n\nCycle 13 Week 2 (C13W2):\n\nDays 1-3: 5 mg daily (1 × 5 mg tablet); Days 4-7: 10 mg daily (2 × 5 mg tablets)\n\nCycle 13 Week 3 (C13W3):\n\nDays 1-3: 20 mg daily (1 × 20 mg tablet); Days 4-7: 40 mg daily (2 × 20 mg tablets)\n\nCycle 13 Week 4 (C13W4):\n\nDays 1-3: 80 mg daily (1 × 80 mg tablet); Days 4-7: 160 mg daily (2 × 80 mg tablets) Cycle 14 Week 1 (C14W1) and all subsequent cycles: 320 mg daily (4 × 80 mg tablets)",[15,9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"zanubrutinib maintenance until disease progression","Continuous zanubrutinib monotherapy until disease progression or intolerable toxicity occurs.",[15],[31],{"name":32,"affiliation":33,"role":34},"Shuhua Yi, Docter","Blood Disease Hospital of Chinese Academy of Medical Sciences (Institute of Hematology, CAMS)","PRINCIPAL_INVESTIGATOR",[36,41],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Shuhua Yi, Doctor","CONTACT","（+86）15900265415","yishuhua@ihcams.ac.cn",{"name":42,"role":38,"phone":25,"phoneExt":25,"email":43},"Tingyu Wang, Doctor","wangtingyu@ihcams.ac.cn",[45,62,76,90,104,118,132],{"facility":46,"status":25,"city":47,"state":48,"zip":25,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Shenzhen Second People's Hospital","Shenzhen","Guangdong","China","CN",{"type":52,"coordinates":53},"Point",[54,55],114.0683,22.54554,{"lat":55,"lon":54},[58],{"name":59,"role":38,"phone":60,"phoneExt":25,"email":61},"xiaoqing li","（+86）18620385718","18620385718@163.com",{"facility":63,"status":25,"city":64,"state":65,"zip":25,"country":49,"countryCode":50,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Henan Cancer Hospital","Zhengzhou","Henan",{"type":52,"coordinates":67},[68,69],113.64861,34.75778,{"lat":69,"lon":68},[72],{"name":73,"role":38,"phone":74,"phoneExt":25,"email":75},"keshu zhou","（+86）13674902391","dr_zkshu23810@163.com",{"facility":77,"status":25,"city":78,"state":79,"zip":25,"country":49,"countryCode":50,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"The Second Xiangya Hospital of Central South University","Changsha","Hunan",{"type":52,"coordinates":81},[82,83],112.97087,28.19874,{"lat":83,"lon":82},[86],{"name":87,"role":38,"phone":88,"phoneExt":25,"email":89},"hongling peng","（+86）18900766137","577769365@qq.com",{"facility":91,"status":25,"city":92,"state":93,"zip":25,"country":49,"countryCode":50,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"Jiangsu Province Hospital","Nanjing","Jiangsu",{"type":52,"coordinates":95},[96,97],118.77778,32.06167,{"lat":97,"lon":96},[100],{"name":101,"role":38,"phone":102,"phoneExt":25,"email":103},"huayuan zhu","（+86）13813810650","huayuan.zhu@hotmail.com",{"facility":105,"status":25,"city":106,"state":107,"zip":25,"country":49,"countryCode":50,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"The First Affiliated Hospital of Nanchang University","Nanchang","Jiangxi",{"type":52,"coordinates":109},[110,111],115.85306,28.68396,{"lat":111,"lon":110},[114],{"name":115,"role":38,"phone":116,"phoneExt":25,"email":117},"fei li","（+86）13970038386","yx021021@sina.com",{"facility":119,"status":25,"city":120,"state":121,"zip":25,"country":49,"countryCode":50,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"Qilu Hospital of Shandong University","Jinan","Shandong",{"type":52,"coordinates":123},[124,125],116.99722,36.66833,{"lat":125,"lon":124},[128],{"name":129,"role":38,"phone":130,"phoneExt":25,"email":131},"jingjing ye","（+86）18560086995","yejingjing@sdu.edu.cn",{"facility":33,"status":25,"city":133,"state":134,"zip":135,"country":49,"countryCode":50,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"Tianjin","Tianjin Municipality","300000",{"type":52,"coordinates":137},[138,139],117.17667,39.14222,{"lat":139,"lon":138},[142,143],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},{"name":42,"role":38,"phone":25,"phoneExt":25,"email":43},{"type":145,"investigatorFullName":146,"investigatorTitle":147,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Yi Shuhua","professor",[149],{"name":150,"class":151},"BeOne Medicines","INDUSTRY","100645345","phase-2-zanubrutinib-induction-followed-by-delayed-fixed-duration-combination-with-sonrotoclax-for-cllsllstop-trial-20-100645345",false,"NCT07682415","Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL\u002FSLL：Stop Trial 2.0","A Single-arm, Multicenter, Prospective Phase II Clinical Trial of Delayed Fixed-duration Combination With Sotoraclax Following Zanubrutinib Induction in Patients With CLL\u002FSLL: Stop Trial 2.0","ZS","Inclusion Criteria:\n\n1. Aged ≥18 years, no restriction on gender.\n2. Newly diagnosed chronic lymphocytic leukemia\u002Fsmall lymphocytic lymphoma (CLL\u002FSLL) consistent with the Chinese Guidelines for the Diagnosis and Treatment of Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma (2025 Edition).\n3. Meet at least one of the following indications for CLL treatment:\n\n   1. Evidence of progressive bone marrow failure manifested by progressive reduction in hemoglobin and\u002For platelet counts.\n   2. Massive splenomegaly (spleen palpable \\>6 cm below the left costal margin) or symptomatic splenomegaly.\n   3. Bulky lymphadenopathy (maximum diameter \\>10 cm) or symptomatic lymphadenopathy.\n   4. Progressive lymphocytosis: ≥50% increase in lymphocyte count within 2 months, or lymphocyte doubling time (LDT) \\\u003C6 months. LDT alone shall not serve as an indication for treatment if the baseline lymphocyte count is \\\u003C30×10⁹\u002FL.\n   5. Symptomatic organ dysfunction caused by CLL\u002FSLL (involving skin, kidney, lung, spine and other organs).\n   6. Autoimmune hemolytic anemia (AIHA) and\u002For immune thrombocytopenia (ITP) with inadequate response to corticosteroid therapy.\n   7. At least one of the following disease-related B symptoms:\n\n      * Unintentional weight loss ≥10% within the preceding 6 months without identifiable cause; ② Severe fatigue (ECOG performance status ≥2, inability to perform routine daily activities);\n\n        ③ Unexplained fever \\>38.0 °C lasting ≥2 weeks without confirmed infection;\n\n        ④ Unexplained night sweats persisting for more than 1 month without confirmed infection.\n4. ECOG performance status ≤2.\n5. Major organ function meets the following criteria within 7 days prior to treatment initiation:\n\n   ￮ Hematology: platelet count ≥30×10⁹\u002FL;\n\n   ￮ Biochemistry: total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; creatinine clearance ≥30 mL\u002Fmin;\n\n   ￮ Cardiac Doppler echocardiography: left ventricular ejection fraction (LVEF) ≥lower limit of normal (50%).\n6. Male and female participants agree to use effective contraception throughout the study period and for a minimum of 4 weeks after treatment completion.\n7. Estimated life expectancy ≥6 months.\n8. The patient voluntarily participates in the trial and signs the written informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Previously received any systemic anti-tumor therapy for CLL\u002FSLL. 2. Pathologically confirmed transformation to Richter's syndrome via biopsy. 3. Severe non-lymphoma-related hepatic or renal impairment defined as: ALT\u002FAST \\>3×ULN or TBIL \\>2×ULN; creatinine clearance \\\u003C30 mL\u002Fmin or serum creatinine \\>2×ULN.\n\n  4\\. Significant pre-existing renal, neurological, psychiatric, pulmonary, endocrine, metabolic, immune, cardiovascular or hepatic disease judged by the investigator to compromise trial participation.\n\n  5\\. Other uncontrolled clinically significant medical conditions including but not limited to:\n\n  a. Uncontrolled systemic infection (viral, bacterial, fungal); positive hepatitis B surface antigen with HBV-DNA \\>1000 IU\u002FmL; positive anti-HCV antibody or detectable HCV-RNA; positive anti-HIV antibody.\n\n  b. Active uncontrolled autoimmune diseases other than autoimmune cytopenias. 6. Clinical signs of central nervous system (CNS) dysfunction or documented CNS infiltration by disease.\n\n  7\\. Received major surgery (excluding lymph node biopsy) within 14 days prior to enrollment or scheduled to undergo major surgery during trial treatment.\n\n  8\\. Inability to swallow capsules, malabsorption syndrome, or severe gastrointestinal disorders including prior gastrectomy, small bowel resection, symptomatic inflammatory bowel disease, ulcerative colitis, partial or complete intestinal obstruction.\n\n  9\\. Concurrent use of strong CYP3A inhibitors or inducers during study drug initiation and dose titration period.\n\n  10\\. Pregnant or breastfeeding females; females of childbearing potential without reliable contraceptive measures.\n\n  11\\. Clinically significant cardiovascular disease (NYHA cardiac functional class III\u002FIV); history of myocardial infarction, malignant arrhythmia (including QTc ≥480 ms), inadequately controlled hypertension (systolic BP ≥150 mmHg, diastolic BP ≥100 mmHg) or unstable angina within 6 months before enrollment.\n\n  12\\. Coagulopathy-related exclusion: long-term treatment with multiple high-dose anticoagulants with no possibility of short-term discontinuation; persistent uncontrolled active bleeding; or prior life-threatening irreversible bleeding events.\n\n  13\\. History of severe hypersensitivity to any active ingredient or excipient of the investigational product.\n\n  14\\. Systemic disorders that may impair patient compliance with trial requirements.","ALL","18 Years",{"count":163,"type":164},60,"ESTIMATED","INTERVENTIONAL",[167],"PHASE2","The goal of this clinical trial is to learn if zanubrutinib induction followed by delayed fixed-duration combination with sonrotoclax works to treat previously untreated Chronic Lymphocytic Leukemia (CLL)\u002FSmall Lymphocytic Lymphoma (SLL). It will also learn about the safety of this combination regimen. The main questions it aims to answer are:Does this combination therapy achieve undetectable minimal residual disease (uMRD) in participants?What medical problems (adverse events) do participants have when taking zanubrutinib and sonrotoclax?Researchers will conduct a single-arm study to systematically evaluate the MRD clearance, efficacy, safety, and immune-related functions of this specific treatment sequence.Participants will:Low-risk group (without 17p deletion\u002FTP53 mutation): Take zanubrutinib monotherapy for 12 cycles, followed by combination zanubrutinib + sonrotoclax for 12 cycles, then discontinue treatment for observation.High-risk group (with 17p deletion\u002FTP53 mutation): Follow the same initial regimen (12 cycles monotherapy + 12 cycles combination), followed by zanubrutinib monotherapy maintenance until disease progression.Visit the clinic periodically for MRD assessment (via flow cytometry), efficacy evaluation (CT\u002FPET-CT, lab tests), and safety checks (physical exam, blood tests, ECG).Undergo immune function evaluation via peripheral blood samples to assess changes in T-cell counts and subsets.",[170],"CLL \u002F SLL",[172,173,174],"Zanubrutinib","Sonrotoclax","Chronic Lymphocytic Leukemia","NOT_YET_RECRUITING","2026-06-28",{"date":178,"type":179},"2026-07-02","ACTUAL",{"date":181,"type":164},"2026-06-08",{"date":183,"type":164},"2034-08-01",{"name":146,"class":6},7]